4/A: Keros Therapeutics Director Amends SEC Filing to Disclose Previously Omitted Indirect Shareholdings

Keros Therapeutics, Inc. Director and 10% Owner, Tomer Kariv, has filed an amended Form 4 to disclose 155,262 shares of common stock held indirectly, which were inadvertently omitted from prior filings.

Summary

• Tomer Kariv, a Director and 10% Owner of Keros Therapeutics, Inc. (KROS), filed a Form 4/A to amend previous beneficial ownership statements.
• The amendment discloses 155,262 shares of Keros Therapeutics Common Stock beneficially owned indirectly.
• These shares are held by Pontifax Late Stage Fund, L.P. ('Late Stage').
• Mr. Kariv, through his association with Pontifax Management 4 G.P. (2015) Ltd., may be deemed to share voting and dispositive power over these shares.
• The indirect holdings were inadvertently omitted from Forms 4 filed on November 30, 2022, and June 6, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. While the initial omission was a negative, the act of correcting it through an amendment demonstrates a commitment to compliance and transparency, which is a positive for corporate governance.

Positives

• The filing demonstrates a commitment to regulatory compliance by correcting a past omission.
• Increased transparency regarding the full extent of beneficial ownership by a key insider and 10% owner.

Negatives

• The inadvertent omission of significant indirect shareholdings from previous SEC filings indicates a past reporting error or oversight.

Risks

• Past administrative oversight in SEC reporting, though now corrected, could raise questions about internal compliance procedures.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's financial performance or strategic direction.

Management Comments

• "Each of Management 4, Late Stage GP and the Reporting Person disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise."

Industry Context

This filing is a standard regulatory disclosure required for insiders and significant shareholders, reflecting ongoing compliance with U.S. securities laws. It does not provide insights into broader industry trends or competitive landscape, focusing solely on an individual's beneficial ownership reporting.

Corporate Governance

Related Party Transactions

• The indirect ownership of shares through Pontifax Late Stage Fund, L.P., where the reporting person may be deemed to share voting and dispositive power due to a strategic alliance agreement, represents a related party arrangement for beneficial ownership.

Stakeholder Impact

• Shareholders: Provides a more complete and accurate picture of beneficial ownership by a significant insider and 10% owner, improving transparency.

Next Steps

• Continued adherence to Section 16 reporting requirements for all future changes in beneficial ownership.

Key Dates

Keywords

Keros Therapeutics, KROS, SEC Form 4/A, Beneficial Ownership, Insider Trading, Director, 10% Owner, Amendment, Pontifax, Common Stock